NCT05551936View on ClinicalTrials.gov

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 26, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2027

Conditions
Follicular Lymphoma
Interventions
DRUG

Bendamustine

90 mg/m\^2 IV Days 1-2, Cycles 1-3

DRUG

Rituximab

375 mg/m\^2 IV Day 1 Cycles 1-6

DRUG

Tazemetostat

RP2D (400, 600, or 800 mg) orally twice daily Cycles 1-6

Trial Locations (5)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

53705

RECRUITING

University of Wisconsin Carbone Cancer Center, Madison

60611

RECRUITING

Northwestern University, Chicago

60612

RECRUITING

University of Illinois Cancer Center, Chicago

08903

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Collaborators (1)

Epizyme, Inc.
All Listed Sponsors
collaborator

Epizyme, Inc.

INDUSTRY

collaborator

University of Wisconsin, Madison

OTHER

lead

Vaishalee Kenkre

OTHER

NCT05551936 - A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | Biotech Hunter | Biotech Hunter